Figures & data
Figure 1 Overview of the relationships between ALSFRS-R, mortality and treatment.
Abbreviation: ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale.
![Figure 1 Overview of the relationships between ALSFRS-R, mortality and treatment.](/cms/asset/a92e731a-8c48-4182-8043-78fc8911b6b7/dcle_a_153196_f0001_b.jpg)
Table 1 Null and alternative hypothesis of each analytical strategy to evaluate the combined treatment effect on survival and functional loss
Figure 2 Rates of functional decline and mortality in the PRO-ACT database with a simulated treatment scenario.
Abbreviations: ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale; PRO-ACT, Pooled Resource Open-Access ALS Clinical Trials.
![Figure 2 Rates of functional decline and mortality in the PRO-ACT database with a simulated treatment scenario.](/cms/asset/7812b61a-080e-4b44-9d65-45eead3f2e6e/dcle_a_153196_f0002_c.jpg)
Table 2 Baseline characteristics of the PRO-ACT database’s placebo patients
Table 3 Empirical power of each strategy for trials with a maximum follow-up duration of 18 months
Figure 3 Empirical power of the four analytical strategies for different treatment scenarios.
Abbreviations: ALSFRS-R, revised amyotrophic lateral sclerosis functional rating scale; CAFS, combined assessment of function and survival; HR, hazard ratio; LME, linear mixed effects; PH, proportional hazard.
![Figure 3 Empirical power of the four analytical strategies for different treatment scenarios.](/cms/asset/5351f1bf-3c21-4da6-9fe0-4f66db79d8c2/dcle_a_153196_f0003_c.jpg)